Search results
Drug names: How companies and regulators come up with hundreds of new names every year
Quartz· 2 days agoEverything you need to know about the art and science of drug naming in five minutes or less,...
Drug shortages keep on growing. Older, injectable medicines are among the most vulnerable
San Francisco Chronicle· 4 days agoErin Fox has tracked drug shortages for more than 20 years, and she sees no easy solutions for what has become a record run. Total active shortages hit an all-time high of ...
Drug shortages keep on growing. Older, injectable medicines are among the most vulnerable
Odessa American· 4 days agoErin Fox has tracked drug shortages for more than 20 years, and she sees no easy solutions for what has become a record run. Total active shortages hit an all-time high of ...
Is Eli Lilly Stock A Buy After FDA Advisors Back Its Alzheimer's Drug?
Investor's Business Daily· 1 day agoThe company also calls for adjusted earnings of $13.50 to $14 a share. Both measures topped...
Eli Lilly is cracking down on knock-off versions of its popular weight loss drug Zepbound
Quartz· 1 day agoEli Lilly said Thursday that it is taking legal action against six entities for selling unapproved...
Drug Names: The machinations behind the monikers
Quartz· 3 days agoIn fact, naming a prescription drug can take a manufacturer up to four years, as a set of three monikers per medicine must run the gauntlet of several regulatory agencies.
Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now
Zacks via Yahoo Finance· 1 day agoThe stock has risen 453% in the past five years, mainly on the success of its drug semaglutide, a...
Gilead Flashes Bullish Sign After HIV Drug Proves 100% Effective
Investor's Business Daily· 1 day agoThe news is a boon for Gilead Sciences (GILD), which already sells its HIV drugs Descovy and Truvada...
Gateway - Quartz
Quartz· 4 days agoThe first biosimilar to enter the market is Amgen’s Amjevita, which was launched in the US on Jan. 31, 2023. The drug will be available in the US at two different
Cencora (COR) Gains 13.2% YTD: What's Driving the Stock?
Zacks via Yahoo Finance· 4 days agoThe generic industry is facing consolidation of customers and manufacturers, global competitors and...